OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
With employers and the public scrutinizing drug prices like never before, rebates-long at the center of pharma’s market access strategy-may be losing their luster, writes Amber Gilbert.
With copay accumulators, payers have drawn a line in the sand. How should pharma respond?